Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash from Investing Activities: 2023-2025

  • Mereo BioPharma Group's Cash from Investing Activities was N/A to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$719,000, marking a year-over-year change of. This contributed to the annual value of -$699,000 for FY2024, which is 66.83% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Cash from Investing Activities is $300,000, which was up 193.75% from -$320,000 recorded in Q1 2025.
  • In the past 5 years, Mereo BioPharma Group's Cash from Investing Activities registered a high of $300,000 during Q3 2025, and its lowest value of -$700,000 during Q1 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$320,000 (2025), whereas its average is -$227,600.
  • Per our database at Business Quant, Mereo BioPharma Group's Cash from Investing Activities crashed by 67.06% in 2024 and then spiked by 54.29% in 2025.
  • Over the past 3 years, Mereo BioPharma Group's Cash from Investing Activities (Quarterly) stood at -$419,000 in 2023, then crashed by 67.06% to $1,000 in 2024, then soared by 54.29% to $300,000 in 2025.
  • Its Cash from Investing Activities was $300,000 in Q3 2025, compared to -$320,000 in Q1 2025 and $1,000 in Q2 2024.